These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 22788233)

  • 1. Using resources for scientific-driven pharmacovigilance: from many product safety documents to one product safety master file.
    Furlan G
    Drug Saf; 2012 Aug; 35(8):615-22. PubMed ID: 22788233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unifying drug safety and clinical databases.
    Burnstead B; Furlan G
    Curr Drug Saf; 2013 Feb; 8(1):56-62. PubMed ID: 23656448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring the manufacturing and quality of medicines: a fundamental task of pharmacovigilance.
    Sardella M; Belcher G; Lungu C; Ignoni T; Camisa M; Stenver DI; Porcelli P; D'Antuono M; Castiglione NG; Adams A; Furlan G; Grisoni I; Hall S; Boga L; Mancini V; Ciuca M; Chonzi D; Edwards B; Mangoni AA; Tuccori M; Prokofyeva E; De Gregorio F; Bertazzoli Grabinski Broglio M; van Leeuwen B; Kruger P; Rausch C; Le Louet H
    Ther Adv Drug Saf; 2021; 12():20420986211038436. PubMed ID: 34394910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aggregate analysis of regulatory authority assessors' comments to improve the quality of periodic safety update reports.
    Jullian S; Jaskiewicz L; Pfannkuche HJ; Parker J; Lalande-Luesink I; Lewis DJ; Close P
    Pharmacoepidemiol Drug Saf; 2015 Sep; 24(9):971-9. PubMed ID: 26175055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacovigilance in Israel - tools, processes, and actions.
    Schwartzberg E; Berkovitch M; Dil Nahlieli D; Nathan J; Gorelik E
    Isr J Health Policy Res; 2017 Aug; 6(1):29. PubMed ID: 28760141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a checklist for the assessment of pharmacovigilance guidelines in Southern Africa: a document review.
    Makhene NL; Steyn H; Vorster M; Lubbe MS; Burger JR
    Ther Adv Drug Saf; 2023; 14():20420986221143272. PubMed ID: 36713000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of completeness of suspected adverse drug reaction reports submitted to the mexican national pharmacovigilance centre: a cross-sectional period-prevalence study.
    Sánchez-Sánchez B; Altagracia-Martínez M; Kravzov-Jinich J; Moreno-Bonett C; Vázquez-Moreno E; Martínez-Núñez JM
    Drug Saf; 2012 Oct; 35(10):837-44. PubMed ID: 22924896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of post-authorization safety studies in the first cohort of EU Risk Management Plans at time of regulatory approval.
    Giezen TJ; Mantel-Teeuwisse AK; Straus SM; Egberts TC; Blackburn S; Persson I; Leufkens HG
    Drug Saf; 2009; 32(12):1175-87. PubMed ID: 19916584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved statistical signal detection in pharmacovigilance by combining multiple strength-of-evidence aspects in vigiRank.
    Caster O; Juhlin K; Watson S; Norén GN
    Drug Saf; 2014 Aug; 37(8):617-28. PubMed ID: 25052742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review of FDA Amendments Act Section 921 Experience in Posting Data-mining Results from the FAERS Database.
    Beninger P; Murray M
    Clin Ther; 2021 Feb; 43(2):380-395. PubMed ID: 33504449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Changing Regulations and the Dynamic Nature of European Risk Management Plans for Human Medicines on the Lifecycle of Safety Concerns.
    Holm JEJ; Ruppert JG; Ramsden SD
    Pharmaceut Med; 2022 Feb; 36(1):33-46. PubMed ID: 35099785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective data mining of six products in the US FDA Adverse Event Reporting System: disposition of events identified and impact on product safety profiles.
    Bailey S; Singh A; Azadian R; Huber P; Blum M
    Drug Saf; 2010 Feb; 33(2):139-46. PubMed ID: 20082540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EudraVigilance Medicines Safety Database: Publicly Accessible Data for Research and Public Health Protection.
    Postigo R; Brosch S; Slattery J; van Haren A; Dogné JM; Kurz X; Candore G; Domergue F; Arlett P
    Drug Saf; 2018 Jul; 41(7):665-675. PubMed ID: 29520645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety signal detection: the relevance of literature review.
    Pontes H; Clément M; Rollason V
    Drug Saf; 2014 Jul; 37(7):471-9. PubMed ID: 24895178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event Reports.
    Hoffman KB; Dimbil M; Tatonetti NP; Kyle RF
    Drug Saf; 2016 Jun; 39(6):561-75. PubMed ID: 26946292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Individual Case Safety Report Replication: An Analysis of Case Reporting Transmission Networks.
    van Stekelenborg J; Kara V; Haack R; Vogel U; Garg A; Krupp M; Gofman K; Dreyfus B; Hauben M; Bate A
    Drug Saf; 2023 Jan; 46(1):39-52. PubMed ID: 36565374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics of drugs safety signals that predict safety related product information update.
    Insani WN; Pacurariu AC; Mantel-Teeuwisse AK; Gross-Martirosyan L
    Pharmacoepidemiol Drug Saf; 2018 Jul; 27(7):789-796. PubMed ID: 29797381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Feasibility Study of Drug-Drug Interaction Signal Detection in Regular Pharmacovigilance.
    Hult S; Sartori D; Bergvall T; Hedfors Vidlin S; Grundmark B; Ellenius J; Norén GN
    Drug Saf; 2020 Aug; 43(8):775-785. PubMed ID: 32681439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.